RTC
ANAB icon

Riverview Trust Company’s AnaptysBio ANAB Stock Holding History

Riverview Trust Company’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-13
Closed -$436 – 826
2024
Q3 		$436 Buy
+13
New +$444 ﹤0.01% 811

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Riverview Trust Company's ANAB Position: Q4 2024 in Review

Riverview Trust Company sold out of AnaptysBio (ANAB) in Q4 2024, closing a stake of 13 shares — an estimated $436 sold.

Riverview Trust Company first reported a position in ANAB in Q3 2024 and held it in 1 quarter. The position peaked at $436 in Q3 2024. 135 funds tracked by Wall St. Rank hold ANAB as of Q4 2024.

  • Riverview Trust Company reported no remaining AnaptysBio position as of Q4 2024 after selling out during the quarter.
  • Riverview Trust Company sold 13 AnaptysBio shares in Q4 2024, an estimated $436.
  • Riverview Trust Company first reported a position in AnaptysBio in Q3 2024 and held it in 1 quarter.
  • Riverview Trust Company's AnaptysBio position peaked at $436 in Q3 2024.
  • 135 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2024.

Based on Riverview Trust Company's 13F filing for Q4 2024, filed 6 Feb 2025.